Activities of Systemically Administered Echinocandins Against in Vivo Mature Candida Albicans Biofilms Developed in a Rat Subcutaneous Model

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2013 Feb 14

PMID 23403433

Citations 19

Authors

Sona Kucharikova

Nidhi Sharma

Isabel Spriet

Johan Maertens

Patrick Van Dijck

Katrien Lagrou

Affiliations

Soon will be listed here.

Abstract

This study addresses the effects of micafungin, caspofungin, and anidulafungin against Candida albicans biofilms developed in a subcutaneous catheter rat model system. Doses of 5, 10, and 30 mg/kg (of body weight)/day (the last only for micafungin) were given intravenously for 5, 7, and 10 days. All three echinocandins caused a significant reduction of the Candida cell numbers on the implanted catheters and are thus promising for the treatment of biofilm-related infections.

Citing Articles

Combination of Systemic and Lock-Therapies with Micafungin Eradicate Catheter-Based Biofilms and Infections Caused by and in Neutropenic Rabbit Models.

Petraitiene R, Petraitis V, Zaw M, Hussain K, Ricart Arbona R, Roilides E J Fungi (Basel). 2024; 10(4).

PMID: 38667964 PMC: 11050883. DOI: 10.3390/jof10040293.

[Chinese expert consensus for invasive fungal disease in patients after hematopoietic stem cell transplantation(2023)].

Zhonghua Xue Ye Xue Za Zhi. 2023; 44(2):92-97.

PMID: 36948861 PMC: 10033276. DOI: 10.3760/cma.j.issn.0253-2727.2023.02.002.

Bioactive Peptides Against Fungal Biofilms.

Oshiro K, Rodrigues G, Monges B, Cardoso M, Franco O Front Microbiol. 2019; 10:2169.

PMID: 31681179 PMC: 6797862. DOI: 10.3389/fmicb.2019.02169.

Effect of Shikonin Against Biofilms.

Yan Y, Tan F, Miao H, Wang H, Cao Y Front Microbiol. 2019; 10:1085.

PMID: 31156594 PMC: 6527961. DOI: 10.3389/fmicb.2019.01085.

Transcriptomic and Genomic Approaches for Unravelling Biofilm Formation and Drug Resistance-An Update.

Chong P, Chin V, Wong W, Madhavan P, Yong V, Looi C Genes (Basel). 2018; 9(11).

PMID: 30405082 PMC: 6266447. DOI: 10.3390/genes9110540.

References

Kucharikova S, Tournu H, Holtappels M, Van Dijck P, Lagrou K . In vivo efficacy of anidulafungin against mature Candida albicans biofilms in a novel rat model of catheter-associated Candidiasis. Antimicrob Agents Chemother. 2010; 54(10):4474-5. PMC: 2944565. DOI: 10.1128/AAC.00697-10. View

Damle B, Stogniew M, Dowell J . Pharmacokinetics and tissue distribution of anidulafungin in rats. Antimicrob Agents Chemother. 2008; 52(7):2673-6. PMC: 2443878. DOI: 10.1128/AAC.01596-07. View

Lazzell A, Chaturvedi A, Pierce C, Prasad D, Uppuluri P, Lopez-Ribot J . Treatment and prevention of Candida albicans biofilms with caspofungin in a novel central venous catheter murine model of candidiasis. J Antimicrob Chemother. 2009; 64(3):567-70. DOI: 10.1093/jac/dkp242. View

Niwa T, Yokota Y, Tokunaga A, Yamato Y, Kagayama A, Fujiwara T . Tissue distribution after intravenous dosing of micafungin, an antifungal drug, to rats. Biol Pharm Bull. 2004; 27(7):1154-6. DOI: 10.1248/bpb.27.1154. View

Theuretzbacher U . Pharmacokinetics/pharmacodynamics of echinocandins. Eur J Clin Microbiol Infect Dis. 2004; 23(11):805-12. DOI: 10.1007/s10096-004-1228-z. View

Sucher A, Chahine E, Balcer H . Echinocandins: the newest class of antifungals. Ann Pharmacother. 2009; 43(10):1647-57. DOI: 10.1345/aph.1M237. View

Kuhn D, George T, Chandra J, Mukherjee P, Ghannoum M . Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother. 2002; 46(6):1773-80. PMC: 127206. DOI: 10.1128/AAC.46.6.1773-1780.2002. View

Ricicova M, Kucharikova S, Tournu H, Hendrix J, Bujdakova H, Van Eldere J . Candida albicans biofilm formation in a new in vivo rat model. Microbiology (Reading). 2009; 156(Pt 3):909-919. DOI: 10.1099/mic.0.033530-0. View

Gillum A, Tsay E, Kirsch D . Isolation of the Candida albicans gene for orotidine-5'-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol Gen Genet. 1984; 198(2):179-82. DOI: 10.1007/BF00328721. View

10.

Shuford J, Rouse M, Piper K, Steckelberg J, Patel R . Evaluation of caspofungin and amphotericin B deoxycholate against Candida albicans biofilms in an experimental intravascular catheter infection model. J Infect Dis. 2006; 194(5):710-3. DOI: 10.1086/506452. View

11.

Pappas P, Kauffman C, Andes D, Benjamin Jr D, Calandra T, Edwards Jr J . Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48(5):503-35. PMC: 7294538. DOI: 10.1086/596757. View

12.

Bachmann S, VandeWalle K, Ramage G, Patterson T, Wickes B, Graybill J . In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob Agents Chemother. 2002; 46(11):3591-6. PMC: 128731. DOI: 10.1128/AAC.46.11.3591-3596.2002. View

13.

Nett J, Marchillo K, Spiegel C, Andes D . Development and validation of an in vivo Candida albicans biofilm denture model. Infect Immun. 2010; 78(9):3650-9. PMC: 2937450. DOI: 10.1128/IAI.00480-10. View

14.

Hajdu R, Thompson R, Sundelof J, Pelak B, Bouffard F, Dropinski J . Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob Agents Chemother. 1997; 41(11):2339-44. PMC: 164125. DOI: 10.1128/AAC.41.11.2339. View